Sign in Subscribe
Medical research

Lecanemab Shows Promise in Treating Alzheimer's Disease

Strategic Insights

— 1 min read

Research on lecanemab, a monoclonal antibody that targets amyloid-beta aggregates, has increased significantly in recent years, with studies suggesting it may be a promising therapeutic for Alzheimer's disease. A new report compiled by researchers at the School of Medicine in Yangzhou, People's Republic of China, analyzed the relevant literature and research trends investigating AD and lecanemab. The study found that the countries with the highest publication output were the United States, the United Kingdom, and China, with leading institutions including Eisai Inc., Uppsala University, and Harvard Medical School.

Key Takeaways:

  • The number of studies published on AD and lecanemab has increased annually, with the United States, the United Kingdom, and China being the top countries for publication output.
  • The leading institutions that produced the most articles were Eisai Inc., Uppsala University, and Harvard Medical School.
  • The top three authors were Lars Lannfelt, Shobha Dhadda, and Michio Kanekiyo, with the most prolific journals including The Journal of Alzheimer's Disease, Alzheimer's and Dementia, and Ageing Research Reviews.
  • The most cited article was 'Lecanemab in Early Alzheimer's Disease,' by Van Dyck et al., published in The New England Journal of Medicine in 2023, which has accrued 172 citations.
  • The 10 most frequently occurring keywords were Alzheimer's disease, lecanemab, dementia, aducanumab, amyloid-beta, immunotherapy, tau, a-beta, mouse model, and donanemab.
  • Text mining revealed that drugs, anatomical structures, chemical molecules, genes, diseases, and procedures were significantly associated with both AD and lecanemab.

Statistics:

  • 172 citations for the article 'Lecanemab in Early Alzheimer's Disease' published in The New England Journal of Medicine in 2023.
  • The countries with the highest publication output were the United States (34%), the United Kingdom (23%), and China (19%).
  • The leading institutions produced a combined total of 103 articles on AD and lecanemab, with Eisai Inc. producing 26 articles, Uppsala University producing 24 articles, and Harvard Medical School producing 22 articles.

Sources:

  • NewsRx. Findings on Alzheimer Disease Described by Researchers at School of Medicine (Mapping the Evolving Landscape of Lecanemab Research in Alzheimer's Disease: A Bibliometric Analysis). Mental Health Weekly Digest. October 13, 2025; p 317.
  • European Journal of Pharmacology, 2025:178187.

Read more